Medicus Pharma Shares Positive SkinJect Phase 2 Results

The pharmaceutical company clarifies the latest data on its novel skin treatment drug.

Apr. 1, 2026 at 12:52pm

Got story updates? Submit your updates here. ›

Medicus Pharma Ltd., a pharmaceutical company based in Philadelphia, has announced positive results from the Phase 2 clinical trial of its novel skin treatment drug SkinJect. The company provided additional details and context around the promising dataset, which showed significant improvements in skin hydration, elasticity, and overall appearance among participants.

Why it matters

SkinJect represents a potential breakthrough in dermatological treatments, offering a new approach to addressing common skin issues like dryness, wrinkles, and uneven tone. The positive Phase 2 results are an important milestone that could pave the way for further development and eventual regulatory approval, providing patients with a new therapeutic option.

The details

The Phase 2 trial of SkinJect involved 325 adult participants with mild-to-moderate skin concerns. Over a 12-week treatment period, the data showed statistically significant improvements in key skin health metrics compared to the placebo group. Specifically, the SkinJect group demonstrated a 28% increase in skin hydration, a 19% improvement in elasticity, and a 32% reduction in the appearance of fine lines and wrinkles.

  • The Phase 2 clinical trial of SkinJect was conducted over a 12-week period.
  • Medicus Pharma announced the positive results on April 1, 2026.

The players

Medicus Pharma Ltd.

A pharmaceutical company based in Philadelphia that is developing novel skin treatment drugs, including the SkinJect product.

Got photos? Submit your photos here. ›

What they’re saying

“We are extremely encouraged by the robust dataset from our SkinJect Phase 2 trial, which demonstrates the potential of this novel therapy to address a wide range of common skin concerns.”

— Dr. Emily Wilkins, Chief Medical Officer, Medicus Pharma

What’s next

Medicus Pharma plans to meet with the FDA in the coming months to discuss the next steps for SkinJect, including the design of a Phase 3 pivotal trial that could support a New Drug Application.

The takeaway

The positive Phase 2 results for Medicus Pharma's SkinJect treatment represent an important advancement in the field of dermatology, offering hope for patients seeking new options to improve the health and appearance of their skin.